Key facts
- This page summarizes Scott Centea's Form 4 filing for ANGIODYNAMICS INC (ANGO).
- 3 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 21 Jul 2023, 21:11.
Scott Centea - 19 Jul 2023 Form 4 Insider Report for ANGIODYNAMICS INC (ANGO)
- Reporting relationship
- SVP/GM, VIT
- Issuer ticker
- ANGO
- Reported as of
- 19 Jul 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 21 Jul 2023, 21:11:19 UTC
- Prior SEC filing
- 18 Jul 2023
- Next SEC filing
- 25 Jul 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Stephen A. Trowbridge, Attorney in Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Scott Centea filed Form 4 for ANGIODYNAMICS INC (ANGO) on 21 Jul 2023.
Change
- Previous filing in this sequence was filed on 18 Jul 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ANGO
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +10,588
- Change %
- +22%
- Price
- $0.000000
- Shares after
- 58,716
- Date
- 19 Jul 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ANGO
transaction
Derivative
Performance Right
Award
- Transaction value
- $0
- Shares
- +21,176
- Change %
- Price
- $0.000000
- Shares after
- 21,176
- Date
- 19 Jul 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 21,176
- Exercise price
- Footnotes
- F2
ANGO
transaction
Derivative
Non-Qualified Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +21,913
- Change %
- Price
- $0.000000
- Shares after
- 21,913
- Date
- 19 Jul 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 21,913
- Exercise price
- $8.92
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The acquisition of 10,588 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 10,588 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 19, 2024, such that 25% of the restricted stock units will vest on each of July 19, 2024, 2025, 2026 and 2027.
Footnote F2
Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned over a three-year performance period in accordance with performance metrics as determined by the compensation committee (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)). Any shares that do not vest at the end of the performance period will be forfeited.
Footnote F3
These stock options vest in four equal annual installments beginning on July 19, 2024, such that 25% of the options will vest on each of July 19, 2024, 2025, 2026 and 2027.